跳至主要内容
临床试验/NCT04515524
NCT04515524进行中(未招募)不适用

An Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study

Regeneron Pharmaceuticals30 个研究点 分布在 10 个国家目标入组 100 人开始时间: 2021年2月5日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
100
试验地点
30
主要终点
Proportion of Patients with Serious Adverse Events

研究概览

简要总结

Primary objectives of the study are:

  • To evaluate binocular visual acuity at the end of this study in patients included from the VGFTe-ROP-1920 study, for treatment of Retinopathy of Prematurity (ROP).
  • To evaluate long-term safety outcomes in patients included from the VGFTe-ROP-1920 study, for treatment of ROP.

Secondary objectives of the study are:

  • To describe visual function in patients included from the VGFTe-ROP-1920 study, for treatment of ROP.
  • To describe overall development in patients included from the VGFTe-ROP-1920 study, for treatment of ROP.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
11 Months 至 5 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Patient was treated in study VGFTe-ROP-1920
  • Age <13 months of chronological age
  • Signed informed consent from parent(s)/legal guardian(s), which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol

排除标准

  • Patient has a condition preventing participation in the study, or performance of study procedures
  • NOTE: Other Inclusion/Exclusion criteria may apply

结局指标

主要结局

Proportion of Patients with Serious Adverse Events

时间窗: Up to 5 years of chronological age

Binocular best-corrected visual acuity (BCVA)

时间窗: 5 years of chronological age

Proportion of Patients with Adverse Events

时间窗: Up to 5 years of chronological age

次要结局

  • BCVA in each eye(3 year of chronological age, 5 years of chronological age)
  • Neurodevelopmental outcomes using BSID-III(2 years of chronological age)
  • Neurodevelopmental outcomes using WPPSI-IV(5 years of chronological age)
  • Proportion of patients with recurrence of ROP(3 years of chronological age, 5 years of chronological age)
  • Proportion of patients requiring treatment for ROP(Through 5 years of chronological age)
  • Proportion of patients developing unfavorable ocular structural outcome(3 years of chronological age, 5 years of chronological age)
  • Refractive spherical equivalent in each eye(3 years of chronological age, 5 years of chronological age)
  • Neurodevelopmental outcomes using VABS-II(2 years of chronological age, 5 years of chronological age)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (30)

Loading locations...

相似试验

Extension Study to Evaluate the Long-Term Outcomes... | 临床试验